Search - tctmd.com

Displaying 181 - 200 of 239

Sort: Relevancy | Date

Cancer Survivors With Heart Failure Respond Well to CRT

News Conference News HRS 2019

Cancer Survivors With Heart Failure Respond Well to CRT

May 14, 2019

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

News Daily News

Registries Point to Lower Risk of Death With CABG vs PCI in Multivessel CAD

Michael O'Riordan

May 02, 2019

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

News Daily News

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

Michael O'Riordan

April 12, 2019

Sonothrombolysis for Acute STEMI? High-Frequency Microbubbles Show Promise in MRUSMI

News Conference News ACC 2019

Sonothrombolysis for Acute STEMI? High-Frequency Microbubbles Show Promise in MRUSMI

March 27, 2019

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

News Daily News

AHA Warns of Stagnating CVD Gains, Barriers to Access, and Dismal Drug Pipeline

Michael O'Riordan

January 29, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

Cancer Patients Should Not Be Automatically Ruled Out for TAVR: Analysis

News Daily News

Cancer Patients Should Not Be Automatically Ruled Out for TAVR: Analysis

January 10, 2019

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

News Conference News TCT 2018

Denervation Has Possible Benefit for Pulmonary Hypertension Related to Left Heart Failure

September 23, 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

August 26, 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

News Conference News ESC 2018

CLARIFY: No Survival Benefit With Beta-Blockers Beyond 1 Year Post-MI in Stable CAD

August 25, 2018

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

News Daily News

Coronary Microvascular Dysfunction May Be a Marker of CV Risk in Obese Patients

August 09, 2018

After Cardiotoxic Chemo, Less Than Half of Women With Breast Cancer Get Recommended Monitoring

News Daily News

After Cardiotoxic Chemo, Less Than Half of Women With Breast Cancer Get Recommended Monitoring

August 06, 2018

News Industry News

Abott Implements Corrective Action for Heartmate 3 Heart Pump

May 07, 2018

Fewer Complications, Lower Risk of Death With Conscious Sedation for TAVR

News Daily News

Fewer Complications, Lower Risk of Death With Conscious Sedation for TAVR

Michael O'Riordan

March 27, 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

News Conference News ACC 2018

ACC 2018, Day One: Live From Orlando! The ODYSSEY Begins

March 10, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

News Daily News

Diabetes, Multivessel CAD, and LV Dysfunction? Registry Analysis Gives CABG the Edge Over PCI

Michael O'Riordan

February 20, 2018

AHA Releases Scientific Statement on Breast Cancer and CVD

News Daily News

AHA Releases Scientific Statement on Breast Cancer and CVD

February 01, 2018

Surprising Rate of Cardiac Amyloidosis in TAVR Patients Poses Tough Questions for Diagnosis, Decision-Making

News Daily News

Surprising Rate of Cardiac Amyloidosis in TAVR Patients Poses Tough Questions for Diagnosis, Decision-Making

Michael O'Riordan

February 01, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.